Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto Prefecture.

Kajiwara, Ayami; Saruwatari, Junji; Sakata, Misaki; Morita, Kazunori; Kita, Ayana; Oniki, Kentaro; Yamamura, Masato; Murase, Motoji; Koda, Haruo; Hirota, Seisuke; Ishizuka, Tadao; Nakagawa, Kazuko

Kajiwara, Ayami; Saruwatari, Junji; Sakata, Misaki; Morita, Kazunori; Kita, Ayana; Oniki, Kentaro; Yamamura, Masato; Murase, Motoji; Koda, Haruo; Hirota, Seisuke; Ishizuka, Tadao; Nakagawa, Kazuko.

Affiliation

Kajiwara A; Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Kumamoto, 862-0973, Japan.

Drug Saf ; 36(10): 981-7, 2013 Oct.

Article de En | MEDLINE | ID: mdl-23743694

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Systèmes de signalement des effets indésirables des médicaments / Inhibiteurs de la dipeptidyl-peptidase IV / Hypoglycémie / Hypoglycémiants Type d'étude: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Qualitative_research / Systematic_reviews Limites: Aged / Female / Humans / Male Pays/Région comme sujet: Asia Langue: En Journal: Drug Saf Sujet du journal: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Année: 2013 Type de document: Article Pays d'affiliation: Japon Pays de publication: Nouvelle-Zélande

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google